Cargando…

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients

Aims. To examine the potential differences between multiple daily injection (MDI) regimens based on new long-acting insulin analogues (glargine or detemir) plus prandial insulin aspart and continuous subcutaneous insulin aspart infusion (CSII) in patients with poorly controlled type 2 diabetes. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Wen-shan, Li, Li, Wen, Jun-ping, Pan, Rong-fang, Sun, Rui-xia, Wang, Jing, Xian, Yu-xin, Cao, Cai-xia, Gao, Yan-yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662171/
https://www.ncbi.nlm.nih.gov/pubmed/23737776
http://dx.doi.org/10.1155/2013/614242
_version_ 1782270815575736320
author Lv, Wen-shan
Li, Li
Wen, Jun-ping
Pan, Rong-fang
Sun, Rui-xia
Wang, Jing
Xian, Yu-xin
Cao, Cai-xia
Gao, Yan-yan
author_facet Lv, Wen-shan
Li, Li
Wen, Jun-ping
Pan, Rong-fang
Sun, Rui-xia
Wang, Jing
Xian, Yu-xin
Cao, Cai-xia
Gao, Yan-yan
author_sort Lv, Wen-shan
collection PubMed
description Aims. To examine the potential differences between multiple daily injection (MDI) regimens based on new long-acting insulin analogues (glargine or detemir) plus prandial insulin aspart and continuous subcutaneous insulin aspart infusion (CSII) in patients with poorly controlled type 2 diabetes. Methods. Patients (n = 119) with poorly controlled type 2 diabetes of a duration exceeding five years were randomly assigned into three groups: Group A treated with CSII using insulin aspart; Group B treated with glargine-based MDI and Group C treated with detemir-based MDI. Results. Good glycemic control was achieved by patients in Group A in a significantly shorter duration than patients in Groups B and C. Total daily insulin, basal insulin dose and dose per kg body weight in Group A were significantly less than those in Groups B and C. Daily blood glucose fluctuation in Group A was significantly less than that in Groups B and C. There were no differences between Groups B and C. Conclusions. Aspart-based CSII may achieve good blood glucose control with less insulin doses over a shorter period compared with glargine or detemir-based MDI. No differences between glargine- and detemir-based MDI were detected in poorly controlled subjects with type 2 diabetes.
format Online
Article
Text
id pubmed-3662171
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36621712013-06-04 Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients Lv, Wen-shan Li, Li Wen, Jun-ping Pan, Rong-fang Sun, Rui-xia Wang, Jing Xian, Yu-xin Cao, Cai-xia Gao, Yan-yan Int J Endocrinol Research Article Aims. To examine the potential differences between multiple daily injection (MDI) regimens based on new long-acting insulin analogues (glargine or detemir) plus prandial insulin aspart and continuous subcutaneous insulin aspart infusion (CSII) in patients with poorly controlled type 2 diabetes. Methods. Patients (n = 119) with poorly controlled type 2 diabetes of a duration exceeding five years were randomly assigned into three groups: Group A treated with CSII using insulin aspart; Group B treated with glargine-based MDI and Group C treated with detemir-based MDI. Results. Good glycemic control was achieved by patients in Group A in a significantly shorter duration than patients in Groups B and C. Total daily insulin, basal insulin dose and dose per kg body weight in Group A were significantly less than those in Groups B and C. Daily blood glucose fluctuation in Group A was significantly less than that in Groups B and C. There were no differences between Groups B and C. Conclusions. Aspart-based CSII may achieve good blood glucose control with less insulin doses over a shorter period compared with glargine or detemir-based MDI. No differences between glargine- and detemir-based MDI were detected in poorly controlled subjects with type 2 diabetes. Hindawi Publishing Corporation 2013 2013-05-08 /pmc/articles/PMC3662171/ /pubmed/23737776 http://dx.doi.org/10.1155/2013/614242 Text en Copyright © 2013 Wen-shan Lv et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lv, Wen-shan
Li, Li
Wen, Jun-ping
Pan, Rong-fang
Sun, Rui-xia
Wang, Jing
Xian, Yu-xin
Cao, Cai-xia
Gao, Yan-yan
Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
title Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
title_full Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
title_fullStr Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
title_full_unstemmed Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
title_short Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
title_sort comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662171/
https://www.ncbi.nlm.nih.gov/pubmed/23737776
http://dx.doi.org/10.1155/2013/614242
work_keys_str_mv AT lvwenshan comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT lili comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT wenjunping comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT panrongfang comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT sunruixia comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT wangjing comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT xianyuxin comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT caocaixia comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients
AT gaoyanyan comparisonofamultipledailyinsulininjectionregimenglargineordetemironcedailyplusprandialinsulinaspartandcontinuoussubcutaneousinsulininfusionaspartinshorttermintensiveinsulintherapyforpoorlycontrolledtype2diabetespatients